DRREDDYBSEDr Reddys Laboratories Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 30 Jun, 2026 · 19:12 IST

Dr Reddy's files FY2026 Integrated Annual Report, BRSR, and AGM notice

Exceptional ItemEbitda Margin CompressionResults View source PDFExplain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹1359.20
prior close
₹1351.00
announcement price
After-mkt
timing
Nifty 100market+0.6%-2.1% vs market
Pharmaceuticals peers, median of 165sector-0.0%-1.5% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty 100 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
+0.1
15m
+0.2
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.5+0.6-2.1-0.0-1.5
Next day
-1.1+1.3-2.4+0.1-1.2
2d
+0.9+1.6-0.6+0.4+0.5
3d
+0.4+2.2-1.8+0.1+0.3
4d
-0.4+2.0-2.3-0.4+0.0
5d
-0.6-0.1-0.5-1.2+0.6
1w
-8.3+1.4-9.6+0.0-8.3
15d
-13.2+0.6-13.8-1.3-11.8
1m
-14.0+3.9-17.9-1.1-12.9
2m
-13.9+1.0-14.9+1.0-14.9
3m
-11.3-5.6-5.6+0.5-11.8
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Reddy's has submitted its Integrated Annual Report, Business Responsibility and Sustainability Report (BRSR), and 42nd AGM notice for FY2025-26 to stock exchanges, sent electronically to members. Key highlights: revenue at Rs 3,35,933 mn (up 3.2%), EBITDA margin of 22.8% impacted by expected lenalidomide decline and one-off items including inventory adjustments, provisions, and impairment charges. India formulations grew 16%. Total 220 new product launches globally during the year.

Likely market impact

Routine annual filing provides transparency on FY2026 results. EBITDA margin compressed YoY due to one-off charges, though underlying business stays resilient with strong India growth.